TORONTO, March 30, 2015 /CNW/ - Teva Canada Limited, a subsidiary of Teva Pharmaceutical Industries Ltd., announced that Health Canada has approved its application for the generic version of PrBortezomib for Injection for the following indications:
- As part of combination therapy for the treatment of patients with previously untreated multiple myeloma who are unsuitable for stem cell transplantation.
- For the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for stem cell transplantation.
- For the treatment of patients with mantle cell lymphoma who have relapsed or were refractory to at least one prior therapy.
Teva Canada was the lead litigator in successfully challenging the patents protecting Velcade® that would have otherwise impeded generic entry until January 2022.PrVelcade® had annual sales of approximately $93.6 million in Canada, based on IMS Brogan sales data as of January 2015. PrBortezomib for Injection is available immediately in hospital pharmacies across Canada.
"Our litigation success in bringing Bortezomib for Injection to market sooner will save Canadian hospitals millions of dollars between today and when the patent was set to expire in January 2022," said Doug Sommerville, Senior Vice President and General Manager, Teva Canada Limited. "We take pride in our compliance with Health Canada regulations as well as with our litigation leadership to successfully advocate on behalf of patients, provinces and hospitals to bring more affordable, safe medications to the market as soon as possible, leaving value in the system for innovation into the next generation of medicines."
Multiple myeloma is a term that refers to cancer of the plasma cells, found in the bone marrow (the hollow area within the bones of the body). [i] According to the Canadian Cancer Society, it is estimated that 2,600 new cases of multiple myeloma were diagnosed in 2014 (1,450 men and 1,100 women). [ii] Multiple myeloma is the second most prevalent blood cancer after non-Hodgkin's lymphoma. [iii] The second indication for Bortezomib for Injection is for mantle cell lymphoma, which develops in the outer edge of a lymph node, also called the mantle zone. This type of lymphoma makes up about six per cent of all non-Hodgkin lymphomas, usually in adults over the age of 50. [iv]
About Teva Canada Limited
Teva Canada Limited, headquartered in Toronto, has provided affordable healthcare solutions for 50 years, with nearly 200,000 [v] prescriptions filled with our products every day. Originally Novopharm Limited, Teva Canada specializes in the development, production and marketing of high-quality generic prescription pharmaceuticals and through our branded division, Teva Canada Innovation, focuses on a diverse line of innovative products in a variety of therapeutic areas. Teva Canada employs more than 1,300 individuals, markets more than 400 [vi] products in Canada and is a subsidiary of Teva Pharmaceutical Industries Ltd., the world's largest generic drug maker. For more information, visit: www.tevacanada.com or www.tevamakesmedicines.ca.
About Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions to millions of patients every day. Headquartered in Israel, Teva is the world's largest generic medicines producer, leveraging its portfolio of more than 1,000 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. Teva's net revenues in 2014 amounted to $20.3 billion. For more information, visit www.tevapharm.com.
[i] Myeloma Canada. What is Myeloma. http://www.myelomacanada.ca/en/whatismyeloma.htm. Accessed March 2015.
[ii] Canadian Cancer Society. Canadian Cancer Statistics 2014. http://www.cancer.ca/~/media/cancer.ca/CW/cancer%20information/cancer%20101/Canadian%20cancer%20statistics/Canadian-Cancer-Statistics-2014--EN.pdf. Accessed March 2015.
[iii] Myeloma Canada. Incidence and prevalence in Canada. http://www.myelomacanada.ca/en/incidence_prevalence.htm. Accessed March 2015.
[iv] Canadian Cancer Society. Non-Hodgkin lymphoma. http://www.cancer.ca/en/cancer-information/cancer-type/non-hodgkin-lymphoma/non-hodgkin-lymphoma/types-of-nhl/mantle-cell-lymphoma/?region=on. Accessed March 2015.
[v] IMS Compuscript TRx MAT September 2014
[vi] IMS CD&H MAT September 2014
SOURCE Teva Canada Limited
For further information: PR Contact: Teva Pharmaceutical Industries Ltd., Denise Bradley, Sr. Vice President, Global Corporate Reputation, Teva Pharmaceuticals, p. +1.215.591.8974, [email protected]